1 Brain Angiotensinergic Regulation of the Immune System: Implications for Cardiovascular and Neuroendocrine Responses.

2 diabetes and hypertension, as well as obesity and alzheimer’s disease, are linked to hypohydration-induced lower brain volume

3 antibodies to probe endogenous g protein-coupled receptor heteromer expression, regulation and function.

4 Angiotensin II type 2 receptor blocker PD123319 has more beneficial effects than losartan on ischemia/reperfusion injury and oxidative damage in isolated rat heart.

5 Effects of voluntary exercise on blood pressure, angiotensin II, aldosterone, and renal function in two-kidney, one-clip hypertensive rats

6 Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model

7 Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials

8 Critical review of cancer risk associated with angiotensin receptor blocker therapy

9 Effects of voluntary exercise on blood pressure, angiotensin II, aldosterone, and renal function in two-kidney, one-clip hypertensive rats

10 Chronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model

11 Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials

12 Critical review of cancer risk associated with angiotensin receptor blocker therapy

13 Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications

14 Data supporting the angiotensin II activates MEL18 to deSUMOylate HSF2 for hypertension-related heart failure

15 Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

16 Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?

17 Effects of angiotensin-II on brain endothelial cell permeability via PPARalpha regulation of para- and trans-cellular pathways.

18 Roles of I in the downregulation of eNOS Ser1177 phosphorylation by angiotensin II-activated PP2A.

19 Proactive treatment of angiotensin receptor antibodies in kidney transplantation with plasma exchange and/or candesartan is safe and associated with excellent graft survival at 4 years: A single centre Australian experience

20 Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma

21 Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism

22 Comparison of candesartan and angiotensin-(1-7) combination to mito-TEMPO treatment for normalizing blood pressure and sympathovagal balance in (mREN2)27 rats

23 Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells

24 Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes

25 The effects of angiotensin II receptor antagonist (candesartan) on rat renal vascular resistance

26 Internalization of Constitutively Active N111G Mutant of AT1 Receptor Induced by Angiotensin II–Receptor Antagonists Candesartan, Losartan, and Telmisartan: Comparison With Valsartan

27 Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study

28 Automated multi-step purification protocol for Angiotensin-I-Converting-Enzyme (ACE).

29 [Association between both maternal and fetal angiotensinogen gene single nucleotide polymorphism and preeclampsia/eclampsia].

30 Role of MicroRNAs in Renin-Angiotensin-Aldosterone System-Mediated Cardiovascular Inflammation and Remodeling

31 An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.

32 Investigations into mild electric foot shock stress-induced cognitive enhancement: possible role of angiotensin neuropeptides

33 Association of seminal angiotensinogen with sperm motility and morphology in male infertility.

34 Identification, structure-activity relationship and in silico molecular docking analyses of five novel angiotensin I-converting enzyme (ACE)-inhibitory peptides from stone fish (Actinopyga lecanora) hydrolysates.

35 Angiotensin-converting enzyme gene polymorphism in arrhythmogenic right ventricular dysplasia: is DD genotype helpful in predicting syncope risk?

36 Continuation of angiotensin converting enzyme inhibitors on the day of surgery is not associated with increased risk of hypotension upon induction of general anesthesia in elective non-cardiac surgeries

37 Study of angiotensin converting enzyme (ACE) activity in patients with atherosclerosis and in healthy individuals.

38 The new angiotensin II receptor blocker Edarbi® as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders

39 Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.

40 The Renin-Angiotensin System in the Central Nervous System and Its Role in Blood Pressure Regulation.

41 Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins.

42 Angiotensin II receptor blockade reduces salt sensitivity of blood pressure through restoration of renal nitric oxide synthesis in patients with diabetic nephropathy

43 Purification of fucoxanthin from Sargassum wightii Greville and understanding the inhibition of angiotensin 1-converting enzyme: An in vitro and in silico studies.

44 Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.

45 Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.

46 Integration of Hypernatremia and Angiotensin II by the Organum Vasculosum of the Lamina Terminalis Regulates Thirst.

47 The Other Angiotensin II Receptor: ATR as a Therapeutic Target.

48 Downregulation of miR-96 suppresses the profibrogenic functions of cardiac fibroblasts induced by angiotensin II and attenuates atrial fibrosis by upregulating KLF13.

49 Preparation of soy sauce by walnut meal fermentation: Composition, antioxidant properties, and angiotensin-converting enzyme inhibitory activities.

50 A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).

51 Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.

52 COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations.

53 Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.

54 Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

55 Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?

56 Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension

57 What Solid Organ Transplant Healthcare Providers should know about Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.

58 Intravital Förster resonance energy transfer imaging reveals elevated [Ca2+]i and enhanced sympathetic tone in femoral arteries of angiotensin II-infused hypertensive biosensor mice

59 Angiotensin Receptor Blockers and the Risk of Suicide: An Exercise in the Critical Examination of a Case-Control Study

60 hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study.

61 angiotensin-converting enzyme inhibitors-induced angioedema of the small bowel mimicking postoperative complication

62 a study on the association between angiotensin-i converting enzyme i/d dimorphism and type-2 diabetes mellitus

63 angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor axis and related mechanisms

64 new clinical investigations with selective angiotensin ii receptor blocker therapy in diabetes and renal disease

65 circadian differences in the contribution of the brain renin-angiotensin system in genetically hypertensive mice

66 ace inhibitors &ndash; angiotensin ii receptor antagonists: a useful combination therapy for ischemic heart disease

67 normal-phase thin-layer chromatography of some angiotensin converting enzyme (ace) inhibitors and their metabolites

68 angiotensin-(1–7) promotes resolution of eosinophilic inflammation in an experimental model of asthma

69 peptides derived from rhopilema esculentum hydrolysate exhibit angiotensin converting enzyme (ace) inhibitory and antioxidant abilities

70 angiotensin ii silencing alleviates erectile dysfunction through down-regulating the rhoa/rho kinase signaling pathway in rats with diabetes mellitus

71 propiedades antioxidantes e inhibición de la enzima convertidora de angiotensina i (eca i) de fracciones ultrafiltradas de hidrolizados de hemoglobina bovina

72 interplay of vitamin d, erythropoiesis, and the renin-angiotensin system

73 when should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease?

74 o uso de inibidores da enzima conversora de angiotensina e sua relação com eventos no pós-operatório de cirurgia de revascularização miocárdica the use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of cabg

75 optimization of bromelain-aided production of angiotensin i-converting enzyme inhibitory hydrolysates from stone fish using response surface methodology

76 influence of angiotensin ii subtype 2 receptor (at2r) antagonist, pd123319, on cardiovascular remodelling of aged spontaneously hypertensive rats during chronic angiotensin ii subtype 1 receptor (at1r) blockade

77 association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease

78 role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart

79 angiotensin ii inhibitor facilitates epidermal wound regeneration in diabetic mice

80 interactions between adenosine, angiotensin ii and nitric oxide on the afferent arteriole influence sensitivity of the tubuloglomerular feedback

81 comparative study on angiotensin converting enzyme inhibitory activity of hydrolysate of meat protein of indonesian local livestocks

82 cardiac-autonomic imbalance and baroreflex dysfunction in the renovascular angiotensin-dependent hypertensive mouse

83 sulforaphane prevents angiotensin ii-induced testicular cell death via activation of nrf2

84 the combination of beta blockers and renin-angiotensin system blockers improves survival in incident hemodialysis patients: a propensity-matched study

85 rational drug design and synthesis of molecules targeting the angiotensin ii type 1 and type 2 receptors

86 Southeast Asian medicinal plants with angiotensin converting enzyme (ACE) inhibition properties

87 renin-angiotensin system antagonists, glomerular filtration rate and blood pressure

88 effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study

89 standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats

90 angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – demystifying controversies

91 kinin b1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive.

92 angiotensin receptor blocker add-on therapy in portal hypertension: to use angiotensin receptor blocker or not to use, that is the question

93 delayed angioedema during therapy with angiotensin-converting enzyme inhibitors

94 combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model

95 angiotensin&nbsp;ii receptor blockers in the prevention of complications from atrial fibrillation

96 the role of genetic polymorphisms of the renin–angiotensin system in renal diseases: a meta-analysis

97 anti-inflammatory and antitumor effects of hydroxytyrosol but not oleuropein on experimental glioma in vivo. a putative role for the renin-angiotensin system

98 an angiotensin i converting enzyme polymorphism is associated with clinical phenotype when using differentiation-syndrome to categorize korean bronchial asthma patients

99 examination of the lipid profile in pregnant obese women, considering the allele status of the genes of angiotensin-converting enzyme (ace i / d) and plasminogen-1 (pa-1 4g / 5g) activator-inhibitor

100 nitric oxide regulates angiotensin-i converting enzyme under static conditions but not under shear stress

101 staphylococcal nuclease domain containing-1 (snd1) promotes migration and invasion via angiotensin ii type 1 receptor (at1r) and tgfβ signaling

Keyword Connections

Journals

Research Groups

Bibliographies